Cannabidiol is insoluble in water but soluble in organic solvents such as pentane. At room temperature, it is a colorless crystalline solid. In strongly basic media and the presence of air, it is oxidized to a quinone. Under acidic conditions it cyclizes to THC, which also occurs during pyrolysis (smoking). The synthesis of cannabidiol has been accomplished by several research groups.
Cannabidiol has low affinity for the cannabinoid CB1 and CB2 receptors, although it can act as an antagonist of CB1/CB2 agonists despite this low affinity. Cannabidiol may be an antagonist of GPR55, a G protein-coupled receptor and putative cannabinoid receptor that is expressed in the caudate nucleus and putamen in the brain. It also may act as an inverse agonist of GPR3, GPR6, and GPR12. CBD has been shown to act as a serotonin 5-HT1A receptor partial agonist. It is an allosteric modulator of the μ- and δ-opioid receptors as well. The pharmacological effects of CBD may involve PPARγ agonism and intracellular calcium release.
The good news is that numerous states have enacted legislation that allows for the use of CBD. Just four states (Idaho, South Dakota, Nebraska, and Kansas) forbid any access to marijuana. Ten states and Washington, D.C., currently allow for both medical and recreational use of cannabis, including CBD products. The other 36 states allow for the use of medical cannabis in some form, though some of these relegate this to CBD oil only. cbd oil
WEBSITE DISCLAIMER: Cannabidiol (CBD) has NOT been proven to treat, relieve, nor cure any disease or medical condition listed on this site. The medical studies, controlled tests, and health information offered by Cannabidiol Life on CBDOilsAndEdibles.com (or any variation of the URL) is an expressed summarization of our personal conducted research and it is strictly to be used as our educated opinion. The information provided here is designed to support, NEVER replace, legal or medical guidance provided by certified legal officials or licensed medical professionals. Our products are not for use by or sale to persons under the age of 18 and our products should be used only as directed on the label. It should not be used if you are pregnant or nursing. Consult with a physician before use if you have a serious medical condition or use prescription medications. A Doctor’s advice should be sought before using this and any supplemental dietary product. All trademarks and copyrights are property of their respective owners and are not affiliated with nor do they endorse this product. These statements have not been evaluated by the FDA and any CBD products listed are not intended to diagnose, potentially relieve, cure or prevent any health condition or disease.
Until 2017, products containing cannabidiol marketed for medical purposes were classed as medicines by the UK regulatory body, the Medicines and Healthcare products Regulatory Agency (MHRA) and could not be marketed without regulatory approval for the medical claims. As of 2018, cannabis oil is legal to possess, buy, and sell in the UK, providing the product does not contain more than 0.3% THC and is not advertised as providing a medicinal benefit.
Schizophrenia. Research on the use of cannabidiol for psychotic symptoms in people with schizophrenia is conflicting. Some early research suggests that taking cannabidiol four times daily for 4 weeks improves psychotic symptoms and might be as effective as the antipsychotic medication amisulpride. However, other early research suggests that taking cannabidiol for 14 days is not beneficial. The conflicting results might be related to the cannabidiol dose used and duration of treatment. cannabidiol oil